<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896921</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00056162</org_study_id>
    <nct_id>NCT01896921</nct_id>
  </id_info>
  <brief_title>Switch to Maraviroc + Integrase Inhibitor</brief_title>
  <official_title>Switch to Maraviroc and Integrase Strand Transfer Inhibitor Combination Therapy (a Triple Class-Sparing Regimen) for the Treatment of HIV-1-Infected Patients on Suppressive Antiretroviral Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study proposes to evaluate the combination of maraviroc with an integrase&#xD;
      strand transfer inhibitor (either raltegravir or dolutegravir) in antiretroviral-experienced&#xD;
      patients to document the efficacy, safety, and tolerability of this combination in order to&#xD;
      provide clinicians with a treatment regimen that minimizes the risk of metabolic&#xD;
      complications by avoidance of NRTI/NNRTIs and PIs. The development of an alternative ART&#xD;
      regimen which lessens the risk of metabolic complications could improve long-term adherence&#xD;
      and reduce the risk of certain co-morbidities associated with long-term ART use. If this new&#xD;
      combination is found to be as efficacious as the standard regimen with enhanced tolerability&#xD;
      and improved metabolic effects, there is great potential for altering the current practice of&#xD;
      HIV medicine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Description of the study design:&#xD;
&#xD;
      The study will enroll 30 HIV-infected patients on a stable ART regimen with a suppressed HIV&#xD;
      RNA &lt; 50 copies/ml for at least one year. Patients will be switched to the experimental&#xD;
      regimen (maraviroc 300 mg twice a day plus either raltegravir 400 mg twice a day or&#xD;
      dolutegravir 50 mg once a-day) and followed for 96 weeks. The decision to use raltegravir or&#xD;
      dolutegravir will be left to investigator/subject preference, as the two integrate inhibitors&#xD;
      are largely interchangeable aside from twice daily (raltegravir) vs. daily (dolutegravir)&#xD;
      dosing.&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
        -  The primary endpoint is the proportion of patients virologically suppressed (HIV RNA &lt;&#xD;
           50 copies/ml) at 48 weeks.&#xD;
&#xD;
      Definitions:&#xD;
&#xD;
        -  Virologic suppression is an HIV RNA &lt; 50 copies/ml.&#xD;
&#xD;
        -  Virologic failure is an HIV RNA ≥ 50 copies/ml confirmed on 2 separate occasions,&#xD;
           separated by &gt; 1 week after viral suppression.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  The percent change in total cholesterol, LDL, and HDL at 48 and 96 weeks.&#xD;
&#xD;
        -  The number of adverse events.&#xD;
&#xD;
        -  The proportion of patients who are virologically suppressed (HIV RNA &lt; 50 copies/ml) at&#xD;
           96 weeks.&#xD;
&#xD;
      Exploratory endpoints:&#xD;
&#xD;
        -  Telomerase activity and telomere length measured at baseline and 24, 48, and 96 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Virologically Suppressed (HIV RNA &lt;50 Copies/ml) at 48 Weeks.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of patients virologically suppressed (HIV RNA &lt;50 copies/ml) at 48 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>96 weeks</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Are Virologically Suppressed (HIV RNA &lt; 50 Copies/ml)</measure>
    <time_frame>96 weeks</time_frame>
    <description>Number of patients who are virologically suppressed (HIV RNA &lt; 50 copies/ml)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Maraviroc + Raltegravir or Dolutegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch to Maraviroc + Raltegravir or Dolutegravir</intervention_name>
    <description>Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
    <arm_group_label>Maraviroc + Raltegravir or Dolutegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Age between 18 and 75 years&#xD;
&#xD;
          -  CD4 count nadir ≥ 250 cells/mm3&#xD;
&#xD;
          -  HIV RNA ≤ 50 copies/ml for ≥ 12 months while taking any ART regimen&#xD;
&#xD;
             o One virologic blip ≤ 400 copies/ml permissible within the 12 months&#xD;
&#xD;
          -  CCR5 tropic virus as defined by:&#xD;
&#xD;
               -  trofile/tropism testing if available, OR&#xD;
&#xD;
               -  DNA trofile if no trofile/tropism test available and CD4 nadir 250-499 cells/mm3,&#xD;
                  OR&#xD;
&#xD;
               -  CD4 nadir ≥ 500 cells/mm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 or &gt; 75 years&#xD;
&#xD;
          -  CD4 count nadir &lt; 250 cells/mm3&#xD;
&#xD;
          -  Dual/mixed or X4 tropic virus if tested prior to viral suppression or if performed by&#xD;
             DNA trofile testing at any time&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2.5 times the&#xD;
             upper limits of normal&#xD;
&#xD;
          -  Women who:&#xD;
&#xD;
               -  are currently pregnant or breastfeeding&#xD;
&#xD;
               -  are of child-bearing age and do not agree to remain abstinent or use (or have&#xD;
                  their partner use) an acceptable method of birth control throughout the study.&#xD;
                  Acceptable method of birth control is defined as intrauterine device (IUD),&#xD;
                  diaphragm with spermicide, contraceptive sponge, condom, vasectomy.&#xD;
&#xD;
          -  History of any malignancy except non-melanoma skin cancer&#xD;
&#xD;
          -  Concomitant use of drugs known to impact or be impacted in terms of pharmacokinetics&#xD;
             or drug-drug interactions with either raltegravir or maraviroc. This includes:&#xD;
&#xD;
               -  Inducers of UGT1A1 (such as rifampin, phenytoin, phenobarbital rifabutin, St.&#xD;
                  John's wort)&#xD;
&#xD;
               -  CYP3A inhibitors (such as ketoconazole, itraconazole, clarithromycin, nefazodone,&#xD;
                  and telithromycin)&#xD;
&#xD;
               -  CYP3A inducers (such as rifampin, carbamazepine, phenobarbital and phenytoin)&#xD;
&#xD;
          -  Subject requires or is anticipated to require any of the prohibited medications noted&#xD;
             in the protocol&#xD;
&#xD;
          -  Enrollment in an experimental protocol having received investigational agents&#xD;
             (antiretroviral or non-antiretroviral) within 30 days of study enrollment&#xD;
&#xD;
          -  Chronic active hepatitis B infection as defined by presence of HBsAg&#xD;
&#xD;
          -  Subject has a history or current evidence of any condition, therapy, laboratory&#xD;
             abnormality or other circumstance that might interfere with the patient's&#xD;
             participation for the full duration of the study, such that it is not in the best&#xD;
             interest of the patient to participate.&#xD;
&#xD;
          -  Subject is unlikely to adhere to the study procedures, keep appointments, or is&#xD;
             planning to relocate during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Riedel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Institute of Human Virology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 27, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <results_first_submitted>July 16, 2019</results_first_submitted>
  <results_first_submitted_qc>November 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2019</results_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>David Riedel</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 26, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT01896921/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Maraviroc + Raltegravir or Dolutegravir</title>
          <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks&#xD;
Switch to Maraviroc + Raltegravir or Dolutegravir: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Maraviroc + Raltegravir or Dolutegravir</title>
          <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks&#xD;
Switch to Maraviroc + Raltegravir or Dolutegravir: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="54" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Virologically Suppressed (HIV RNA &lt;50 Copies/ml) at 48 Weeks.</title>
        <description>Number of patients virologically suppressed (HIV RNA &lt;50 copies/ml) at 48 weeks.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Raltegravir or Dolutegravir</title>
            <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks&#xD;
Switch to Maraviroc + Raltegravir or Dolutegravir: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Virologically Suppressed (HIV RNA &lt;50 Copies/ml) at 48 Weeks.</title>
          <description>Number of patients virologically suppressed (HIV RNA &lt;50 copies/ml) at 48 weeks.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of participants with adverse events</description>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Raltegravir or Dolutegravir</title>
            <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks&#xD;
Switch to Maraviroc + Raltegravir or Dolutegravir: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of participants with adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Are Virologically Suppressed (HIV RNA &lt; 50 Copies/ml)</title>
        <description>Number of patients who are virologically suppressed (HIV RNA &lt; 50 copies/ml)</description>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Raltegravir or Dolutegravir</title>
            <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks&#xD;
Switch to Maraviroc + Raltegravir or Dolutegravir: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Are Virologically Suppressed (HIV RNA &lt; 50 Copies/ml)</title>
          <description>Number of patients who are virologically suppressed (HIV RNA &lt; 50 copies/ml)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>96 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Maraviroc + Raltegravir or Dolutegravir</title>
          <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks&#xD;
Switch to Maraviroc + Raltegravir or Dolutegravir: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mechanical fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gregg Brogden</name_or_title>
      <organization>University of Maryland</organization>
      <phone>4107061660</phone>
      <email>gbrogden@ihv.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

